br Therefore through the application of
Therefore, through the application of dynamic magnetic reso-nance imaging in breast cancer adjuvant chemotherapy, dynamic enhanced magnetic resonance imaging can accurately evaluate the neoadjuvant chemotherapy of breast cancer from the microscopic molecular level, and can reflect the microvascular environment and tissue of the lesion. Changes in internal components provide a reliable basis for the diagnosis and treatment of breast cancer. However, there are some shortcomings in the research process. For example, the sample data collection is small and the result is biased to a certain extent. Therefore, the data capacity will be fur-ther increased in the later research process, so that the obtained results are more valuable.
No funding sources.
 Benkert T, Block KT, Heller S, Moccaldi M, Sodickson DK, Kim SG, et al. Comprehensive dynamic contrast-enhanced 3D magnetic resonance imaging of the breast with fat/water separation and high spatiotemporal Fulvestrant using radial sampling, compressed sensing, and parallel imaging. Invest Radiol 2017;52:1.
 Surov A, Meyer HJ, Leifels L, Höhn AK, Richter C, Winter K. Histogram anal-ysis parameters of dynamic contrast-enhanced magnetic resonance imaging can predict histopathological findings including proliferation potential, cellu-larity, and nucleic areas in head and neck squamous cell carcinoma. Oncotarget 2018;9(30):21070–7.
 Liu D, Qian HF. Dynamic contrast-enhanced magnetic resonance imaging permeability parameters monitor the early response to bevacizumab plus chemotherapy in colorectal cancer patients with liver metastases. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2018;40(2):256.
 Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Int J Gynecol Cancer 2017;75(1):284–98.
 Telli ML, Audeh W, Jensen KC, Bose S, Timms K, Gutin A, et al. Abstract P5-06-01: homologous recombination deficiency (HRD) score predicts response to stan-dard neoadjuvant chemotherapy in patients with triple negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Res Treat 2017;75(Suppl.
 Paireder M, Asari R, Kristo I, Rieder E, Tamandl D, Ba-Ssalamah A, et al. Impact of sarcopenia on outcome in patients with esophageal resection fol-lowing neoadjuvant chemotherapy for esophageal cancer. Eur J Surg Oncol 2017;43(2):478–84.
 Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Nakamura Y, et al. Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus. Surg Today 2017;47(1):65–73.
 Ryu JM, Lee SK, Kim JY, Yu J, Kim SW, Lee JE, et al. Predictive factors for nonsentinel lymph node metastasis in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy: nomogram for predicting nonsentinel lymph node metastasis. Clin Breast Cancer 2017;27(Suppl. (6)). S1526820917301453.
 Peng H, Chen L, Li WF, Guo R, Mao YP, Zhang Y, et al. Tumor response to neoad-juvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a randomized phase 3 clinical trial. Cancer 2017;123(9):1643–52.
 Aoyama T, Nishikawa K, Fujitani K, Tanabe K, Ito S, Matsui T, et al. Early results of a randomized two-by-two factorial phase II trial compar-ing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol 2017;28(8).
Please cite this article in press as: Yang C, Zhao H. Application of dynamic magnetic resonance imaging information technology in adjuvant chemotherapy for breast cancer. J Infect Public Health (2019), https://doi.org/10.1016/j.jiph.2019.06.020